38 Lyophilized amniotic membrane for pterygium surgery: long-term outcomes

BMJ Open Ophthalmol. 2022 Nov;7(Suppl 2):A16. doi: 10.1136/bmjophth-2022-EEBA.38.

Abstract

Purpose: To investigate the tolerability, security and long-term efficacy of lyophilized amniotic membrane (LAM) as an alternative to cryopreserved amniotic membrane in pterygium surgery.

Material and methods: Prospective case series of patients with primary nasal pterygium who undergone pterygium surgery and LAM implant either with sutures or glue. Postoperative follow-up was until month 24. Clinical and cosmetic outcomes, quality of life (as ocular comfort), and complications were evaluated.

Results: LAM was stiff and easy to manipulate as well as no tearing occurred during surgery or suturing. 4 patients (3 males) had pterygium surgery and LAM implant two with sutures and the other two with glue. Ocular comfort was checked and similar among those patients with LAM glued or sutured. After 24 months, there were no issues about tolerability or adverse events. Lower cosmetic outcomes (recurrence) were stated in 3 patients.

Conclusion: Our study showed that LAM could be an effective alternative to cryopreserved amniotic membrane for graft after pterygium excision surgery. Its main advantage, storage at room temperature, can make it of immediate availability. Further studies comparing clinical outcomes of pterygium surgery with cryopreserved amniotic membrane versus LAM would confirm the benefits of the last.

MeSH terms

  • Amnion / transplantation
  • Fibrin Tissue Adhesive / adverse effects
  • Humans
  • Male
  • Pterygium* / surgery
  • Quality of Life
  • Recurrence

Substances

  • Fibrin Tissue Adhesive